Impact News +++ Nouveau Monde Graphite plans to raise capital via stock (SeekingAlpha) +++ NOUVEAU MONDE Aktie -4,89%

ADVERUM Aktie

>ADVERUM Performance

1 Woche: 0%

1 Monat: -2,8%

3 Monate: +37,0%

6 Monate: +58,2%

1 Jahr: -29,3%

laufendes Jahr: -23,0%

>ADVERUM Aktie

Name:

ADVERUM BIOTECHNOLOGIES

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00773U2078 / A404YL

Symbol/ Ticker:

AVU0 (Frankfurt) / ADVM (NASDAQ)

Kürzel:

FRA:AVU0, ETR:AVU0, AVU0:GR, NASDAQ:ADVM

Index:

Webseite:

https://adverum.com/

Profil:

Adverum Biotechnologies, Inc. is a biotechnology c..
>Volltext..

Marktkapitalisierung:

82.05 Mio. EUR

Unternehmenswert:

135.7 Mio. EUR

Umsatz:

EBITDA:

-160.44 Mio. EUR

Nettogewinn:

-157.52 Mio. EUR

Gewinn je Aktie:

-7.31 EUR

Schulden:

75.81 Mio. EUR

Liquide Mittel:

22.21 Mio. EUR

Operativer Cashflow:

-117.55 Mio. EUR

Bargeldquote:

0.58

Umsatzwachstum:

-100%

Gewinnwachstum:

-86.31%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 3.843.289 USD.

Suchwörter:

ADVERUM

Letzte Datenerhebung:

18.12.25

>ADVERUM Kennzahlen

Aktien/ Unternehmen:

Aktien: 22.08 Mio. St.

Frei handelbar: 74.55%

Leerverk. Aktien: -

Rückkaufquote: -10.66%

Mitarbeiter: 155

Umsatz/Mitarb.: 0.01 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: 13.17%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -0.01

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -120.47%

Eigenkaprendite: -417.79%

>ADVERUM Peer Group

Es sind 599 Aktien bekannt.

>ADVERUM Chart & Kurs - NASDAQ

>ADVERUM News

10.12.25 - 20:09

XFRA: Deletion of Instruments from Boerse Frankfurt - 10.12.2025 (XETRA)

The following instruments on Boerse Frankfurt do have their last trading day on 10.12.2025. Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.12.2025. ISIN Name AU0000138190 PURE HYDROGEN CORP AU0000327504 THUNDERBIRD RESOURCES CA68387G1046 OPTEGRA VENTURES INC. DK0010304500 VESTJYSK BANK NAM. DK 1 IM00BPLZ1D89 CHALL.ENERGY GR. LS-,01 KYG2296A1094 COLUMBUS CIRCLE CAP CORP. LU2559000059 MOOLE SCIENCE S.A. DL 1 US00773U2078 ADVERUM BIO.INC. US0450551009 ASHTEAD UNSP.ADR/4 LS-,10 US4228191023 HEIDRICK+STRUG.INTL DL-01 US8485741099 SPIRIT AERO.HLDGS A DL-01...

09.12.25 - 15:54	Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies (AFX)
	INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Tuesday said its tender offer to acquire Adverum Biotechnologies expired on December 8, 2025, with 16.49 million shares about 64 percent of ......

09.12.25 - 15:33	Eli Lilly completes acquisition of Adverum Biotechnologies (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.12.25 - 14:30	Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition (PR Newswire)
	INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase......

09.12.25 - 08:45	XFRA: AVU0: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ADVERUM BIO.INC. AVU0 US00773U2078 BAW/UFN...

09.12.25 - 08:06	XFRA: INSTRUMENT_SUSPENSION - US00773U2078 (XETRA)
	Instrument ID [19016517] (AVU0 - US00773U2078) suspended...

09.12.25 - 08:01	Insiderhandel: CHIEF OPERATING OFFICER kauft Aktien von Adverum Biotechnologies im Wert von 211000 USD (Insiderkauf)
	Soparkar, Peter - Vorstand - Tag der Transaktion: 2025-12-05...

09.12.25 - 08:01	Insiderhandel: CEO, PRESIDENT AND DIRECTOR kauft Aktien von Adverum Biotechnologies im Wert von 47000 USD (Insiderkauf)
	Fischer, Laurent - Vorstand - Tag der Transaktion: 2025-12-05...

09.12.25 - 08:01	Insiderhandel: CEO, PRESIDENT AND DIRECTOR kauft Aktien von Adverum Biotechnologies im Wert von 506916 USD (Insiderkauf)
	Fischer, Laurent - Vorstand - Tag der Transaktion: 2025-12-08...

06.12.25 - 02:01	Insiderhandel: Insider verkauft Aktien von Adverum Biotechnologies im Wert von 2200372 USD (Insiderkauf)
	Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-12-04...

04.12.25 - 07:01	Insiderhandel: Insider verkauft Aktien von Adverum Biotechnologies im Wert von 929597 USD (Insiderkauf)
	Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-12-03...

04.12.25 - 07:01	Insiderhandel: Insider verkauft Aktien von Adverum Biotechnologies im Wert von 1260000 USD (Insiderkauf)
	Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-12-01...

04.12.25 - 07:01	Insiderhandel: Insider verkauft Aktien von Adverum Biotechnologies im Wert von 218236 USD (Insiderkauf)
	Leonard, Braden Michael - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-12-02...

18.11.25 - 12:00	The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum (Zacks)
	Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates....

07.11.25 - 14:06	Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors (PR Newswire)
	Dr Fischer brings 30+ years of experience leading and exiting innovative biotech companies focused on developing and commercializing breakthrough therapies, including Adverum Biotechnologies, recently acquired by Eli Lilly Shinobi prepares to advance two immune evasive iPSC therapies......

24.10.25 - 23:33	$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (PR Newswire)
	NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The......

24.10.25 - 19:51	Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders (PR Newswire)
	MILWAUKEE, Oct. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Adverum (Nasdaq: ADVM) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or......

24.10.25 - 17:54	Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections (Benzinga)
	Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones. read more...

24.10.25 - 15:48	Lilly to Buy Eye Gene Therapy Company Adverum Biotechnologies (Bloomberg)
	Eli Lilly & Co. said it reached a deal to buy Adverum Biotechnologies Inc., a company working to treat blindness, for $3.56 a share plus contingent value rights that could bring the value up to $12.47 a share, as it continues a push into gene therapies....

24.10.25 - 15:30	Eli Lilly To Acquire Adverum Biotechnologies In Deal Worth Up To $12.47 Per Share (AFX)
	INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Friday said it has agreed to acquire Adverum Biotechnologies, Inc. (ADVM) in a transaction valued at up to $12.47 per share.Under the terms ......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer lesen kann, der ist niemals einsam. - Prof. Dr. Walter Jens

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram